IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., now recruiting.
Overview
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07441174 by InxMed (Shanghai) Co., Ltd., with 92 participants planned, started 2026-02-28 and due to reach its primary completion in 2031-02-28. Interventions recorded: IN10018 in combination with RNK08954.
Similar pages
not linked directly; found by shared links- Triala Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Shares IN10018, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Shares IN10018 and the tag pipeline.
- TrialIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Shares IN10018 and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.